With consistent results across studies and a clear dose-response signal, Medicus is positioning the program for End-of-Phase 2 engagement with the U.S. Food and Drug Administration (FDA).The data also suggest that some lesions could potentially avoid immediate surgery, indicating a shift toward less invasive treatment approaches within a practical therapeutic window.The topline results, announced in March, from the SKNJCT-003 Phase 2 study indicated that the 200µg dose cohort achieved a 73% clinical clearan ...